Psilocybin Could Help Curb Cravings and Shut Off Appetite

The ongoing obesity epidemic takes up to 2.8 million lives a year, according to the World Health Organization (WHO). In addition, according to the Centers for Disease Control and Prevention (CDC), the prevalence of obesity increased from 30.5% between 1999 and 2000, as noted by Medical News Today, to 42.4% between 2017 and 2018.

One way to potentially treat obesity could be with psilocybin, which reportedly activates serotonin receptors, or "nature's own appetite suppressant," says Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite.”

One of the top companies researching psilocybin and its potential impact on obesity is NeonMind Biosciences (CSE:NEON)(OTC:NMDBF), which is working with Dr. C. Laird Birmingham, a psychiatry professor at the University of British Columbia and an expert in eating disorders. He notes, “Psilocybin has the potential to serve as a new and different tool to help people lose weight and maintain their weight loss by changing their neural pathways,” as quoted by CTV News, adding, there’s potential to “reset the behaviours and cognitions that link life stress and trauma to eating behaviours.”

As we learn even more about psilocybin and how it could impact mental and health issues, some of the other top companies to watch include Mind Medicine Inc. (OTC:MMEDF), Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Numinus Wellness (TSXV:NUMI)(OTC:LKYSF), and Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF).

NeonMind Biosciences (CSE:NEON)(OTC:NMDBF) Just Filed Four New Patent Applications

NeonMind Biosciences just announced that it has filed four new provisional patent applications with the United States Patent and Trademark Office to protect initial data obtained during NeonMind’s preclinical trial.

The provisional patent applications include data derived from NeonMind’s initial preclinical trial that began in November 2020, which examined the potential use of psilocybin as a treatment for weight loss. NeonMind’s proprietary preclinical data shows promise that both low and high dose psilocybin may reduce weight gain and that the reduction in weight gain can occur in a short period of time.

This data has also been included to support NeonMind’s first filed U.S. provisional patent which has a priority date of December 4, 2019, and has been converted to a Patent Cooperation Treaty application. By filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in 152 countries.

“We are encouraged with the preliminary results obtained from our preclinical trial,” says NeonMind President & CEO Robert Tessarolo. “Through an expanded portfolio of patent applications, NeonMind is uniquely positioned to pursue exciting drug development opportunities in the enormously underserved weight management market. There have been so many solutions developed in the past that have disappointed; a new approach is desperately needed. We are actively building out our capabilities to execute the critical phases of drug development needed to support new drug applications to the FDA.”

NeonMind’s patent portfolio has potential rights in 152 countries including the United States. It has filed 10 US provisional patent applications, of which 2 have been converted to PCT applications. The anticipated patent protection expiry of these pending patents is 2041. NeonMind anticipates that its near term activities will support additional applications filed later this year.

Compounds now covered by NeonMind’s pending patents include:

- Psilocin, Psilocybin

- 4-SH-dimethyltryptamine

- 1-methylpsilocin

- 4-fluoro-N,N-dimethyltryptamine

- O-acetylpsilocin

- 4-hydroxy-N-methyl-N-isopropyltryptamine

- 4-hydroxy-N-methyl-N-ethyltryptamine


Treatments that are covered by NeonMind’s pending patents include:

- Aiding Weight Loss

- Obesity

- Compulsive Eating Disorder

- Diet Alteration

- Reduction of Food Cravings

- Decreasing Food Intake

- Complications Associated with Obesity

NeonMind owns 100% of all of Its intellectual property except for patents surrounding LSD, LSA and DMT, of which it owns 80%. Translational Life Sciences Inc. a research collaborator, owns the remaining 20%.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. NeonMind Biosciences Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of NeonMind Biosciences Inc.
Please click here for full disclaimer.

Contact Information:
[email protected]